EML4 and non-small cell lung carcinoma: The success of EGFR and ALK inhibitor therapies in lung cancer patients with EGFR mutations and EML4-ALK translocations initiated the era of targeted therapy in advanced NSCLC [5,8] and shifted treatment from platinum-based chemotherapy to molecularly targeted therapy.